Novel drug delivery systems are engineered based on rational designs, enhancing the delivery and overall performance of existing drugs with respect to conventional systems.

1. Presented by
EWOFERE, EVINA NAOMI
MSc Biotechnology
NIGERIANDEFENCEACADEMY
POSTGRADUATESCHOOL,RIBADUCAMPUS,KADUNA
FACULTYOFSCIENCE
DEPARTMENTOFBIOTECHNOLOGY
AWRITE-UP
ON
NOVEL DRUG DELIVERY SYSTEMS: WITH KEY
INTEREST IN MONOCLONAL ANTIBODIES

2. Introduction
Types of Novel Drug Delivery Systems
Advantages of Novel Drug Delivery Over
Conventional Systems
Monoclonal Antibodies as Vehicles or
Carriers of Novel Drug Delivery Systems
Conclusion
References
Presentation Outline

3. There is a fundamental shift from conventional treatment paradigms to cutting-
edge techniques that reimagine medication administration, radically altering
modern medicine.
INTRODUCTION
A key area of such transformation is the novel drug delivery systems; these systems
offers a ray of hope when drug research advances are hampered by the need to
ensure targeted distribution, improve bioavailability, and reduce adverse effects.
Novel drug delivery systems are engineered based on rational designs, enhancing
the delivery and overall performance of existing drugs with respect to conventional
systems.

4. While many fundamental, conventional approaches are increasingly being
enhanced, they are now being outperformed by novel drug delivery systems.
This rapid transformation is driven by the desire for accuracy, customization,
and effectiveness.
INTRODUCTION CONT’D
Novel drug delivery methods cover many modalities, including nanoparticles,
microneedles, implantable devices, polymeric systems, liposomes, and
monoclonal antibodies.
Recent advancements in novel drug delivery systems allow sustained but
controlled drug delivery, maintaining efficient levels of drugs with reduced
adverse effects (Jain et al., 2014).

5. Enhanced Bioavailability: Bioavailability refers to the percentage of a medicine that reaches
systemic circulation and is known to have great therapeutic impacts. Since many medications
are known to have poor solubility, which results in reduced bioavailability, such poorly soluble
drugs can have their solubility increased by new delivery technologies, including formulations
based on nanotechnology (Cortesi et al., 2017), which will increase their uptake and
bioavailability.
ADVANTAGES OF NOVEL DRUG DELIVERY
SYSTEMS OVER CONVENTIONAL SYSTEMS
Improved Patient Compliance: Novel Drug Delivery supports decreased dosage frequency; long-
acting and extended-release formulations frequently provide less frequent dosage, streamlining
the treatment plan and enhancing patient adherence.
Targeted Drug Delivery: Targeted drug delivery reduces exposure of healthy tissues to the
medication and concentrates the therapeutic impact at the site of action. It lowers the
frequency of adverse effects linked to traditional therapy by reducing the drug's systemic
exposure (Vaibhav et al., 2020).

6. Monoclonal antibodies (mAbs)
are laboratory-engineered
molecules that have been
selectively employed to target
diseased cells, minimizing
damage to healthy tissues
while mimicking the immune
system's ability to fight off
harmful pathogens.
MONOCLONAL
ANTIBODIES
Genetic material is used in gene
therapy to treat or prevent illness.
The target cells receive these
therapeutic genes via vector
systems, frequently viral vectors,
since they are the commonest
delivery vehicles for in vitro and in
vivo therapy due to their high
transfection efficiency/stable
transgene expression.
GENE THERAPYUSING
VECTORSYSTEMS
Electrotransport or
iontophoresis refers to the
process of accelerating the
movement of charged drug
molecules through
biological membranes by
applying an electric field.
ELECTROTRANSPORT
Liposomes are one of the most
researched mechanisms for
targeted drug delivery. They are
membrane lipid bilayers that
completely envelop their
hydrophilic core, and are
phospholipid-based colloidal
vesicular structures.
LIPOSOMES
Types of Novel Drug Delivery Systems
PHYSICAL CHEMICAL

7. MONOCLONAL ANTIBODIES AS CARRIERS/VEHICLES
OF NOVEL DRUG DELIVERY SYSTEMS
(Abbreviation: CDR: complementarity-determining
region; COO-: carboxy terminal; CH: constant domain,
heavy chain, CL: constant domain, light chain; Fab:
fragment antigen-binding; Fc: fragment crystallisable
region, NH3: amino terminal end, S-S: disulfide bond;
VH: variable domain, heavy chain; VL: variable domain,
light chain)
Fig 1. A schematic diagram representing the modular structure of a
monoclonal antibody (mAb) (Awwad and Angkawinitwong, 2018)

8. MONOCLONAL ANTIBODIES AS CARRIERS/VEHICLES
OF NOVEL DRUG DELIVERY SYSTEMS CONT’D
As one of the most significant therapeutic
protein types, monoclonal antibodies
(mAbs) come in handy for treating several
illnesses, including cancer, inflammation,
and autoimmune disorders. These
immunoglobulins are useful in the delivery
of nanoparticles across the surface of
various cancer cells' antigens.
Therapeutic mAb development requires
several intricate procedures, such as
mAb screening, engineering,
manufacturing, and purification. The
efficiency of each stage has increased
as recombinant methods,
bioprocesses, and affinity-based
purification technologies have
advanced (Birch and Racher, 2006)
• Abagovomab - for Ovarian cancer
• Adalimumab - for Crohn’s disease,
Rheumatoid, and Arthritis
• Alemtuzumab - for Multiple
Sclerosis
APPLICATIONS PRODUCTION MECHANISM
THERAPUETIC
MONOCLONAL
ANTIBODIES

9. CONCLUSION
 The way a medicine is administered can significantly affect how effective it is.
Some medications have an ideal concentration range where the most benefit is
obtained; dosages outside or inside of this range might be hazardous or have
no therapeutic effect.
 More effective drug delivery and targeting systems are now being developed
to reduce drug degradation and loss, prevent adverse side effects, boost
medication bioavailability, and raise the percentage of the drug accumulating
in the necessary zone.
 These recent developments have paved the way for numerous research in the
production ribosomes, niosomes, nanoparticles, and monoclonal antibodies
for the treatment of a wide range of diseases, including cancer and
autoimmune diseases.

10. Awwad, S. and Angkawinitwong, U. (2018). Overview of Antibody Drug
Delivery. Pharmaceutics, 10(3):83.
Birch, J.R. and Racher, A.J. (2006). Antibody production. Advanced Drug Delivery Reviews, 58:671–685.
Cortesi R., Esposito E., Drechsler M., Pavoni G., Cacciatore I., Sguizzato M., Di Stefano A. (2017). L-dopa
co-drugs in nanostructured lipid carriers: A comparative study. Material Science and
Engineering, 72:168-176.
Jain, S., Kirar, M., Bindeliya, M., Sen, L., Soni, M., Shan, M., and Jain P. (2022). Novel drug delivery
systems: an overview. Asian Journal of Dental and Health Sciences, 2:33-39.
Vaibhav, A.B., Rahul, S.K., Ashok, Y.C., Rishikesh, S.B. (2020). A review on novel drug delivery
system. Journal of Emerging Technologies and Innovative Research, 7(9):19–27.
REFERENCES

11. THANK YOU